Explore more publications!

Health Wire Syria: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.

Press releases published on January 5, 2026

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
AI Agents Market to Grow 43.3% Annually Through 2030
Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace
NTHU Study Identifies Vulnerability in Cancer Cells: Dual Strategy Induces Ferroptosis
Plum Tree Launches 2026 with Expanded Access to Mental Health Care for Children and Adolescents
Idorsia’s daridorexant in women during menopausal transition age with insomnia
DentPrime Publishes Comprehensive Patient Guidance Framework for Individuals Considering Dental Treatment Abroad
A Better Life Therapy Joins the Lumina Therapy Alliance, Marking a Major Expansion of the Nation’s Gold Standard for Concierge, In-Person Mental Health Care
Pure Radiance Medispa Introduces Seattle’s First FDA-Cleared, Needle-Free Hair Growth Laser With Zero Downtime
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Global Medical Waste Management Market Set to Reach USD 12.2 Billion by 2028 | MarketsandMarkets™
Mainz Biomed Provides Review of 2025 Highlights
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Nxera Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions